MaineHealth Institute for Research, Center for Molecular Medicine, Scarborough, ME, United States.
University of Strasbourg, Pharmacology Department, Strasbourg, France.
Front Endocrinol (Lausanne). 2023 Feb 23;14:1118691. doi: 10.3389/fendo.2023.1118691. eCollection 2023.
Obesity and obesogenic behaviors are positively associated with both monoclonal gammopathy of unknown significance (MGUS) and multiple myeloma (MM). As the only known modifiable risk factor, this association has emerged as a new potential target for MM prevention, but little is known about the mechanistic relationship of body weight with MM progression. Here we summarize epidemiological correlations between weight, body composition, and the various stages of myeloma disease progression and treatments, as well as the current understanding of the molecular contributions of obesity-induced changes in myeloma cell phenotype and signaling. Finally, we outline groundwork for the future characterization of the relationship between body weight patterns, the bone marrow microenvironment, and MM pathogenesis in animal models, which have the potential to impact our understanding of disease pathogenesis and inform MM prevention messages.
肥胖和致肥胖行为与意义未明的单克隆丙种球蛋白病(MGUS)和多发性骨髓瘤(MM)均呈正相关。由于肥胖是唯一已知的可改变的危险因素,因此这种关联已成为 MM 预防的一个新的潜在靶点,但人们对体重与 MM 进展之间的机制关系知之甚少。在这里,我们总结了体重、身体成分与骨髓瘤疾病进展和治疗各个阶段之间的流行病学相关性,以及肥胖引起的骨髓瘤细胞表型和信号变化的分子贡献的现有认识。最后,我们概述了在动物模型中未来表征体重模式、骨髓微环境与 MM 发病机制之间关系的基础工作,这有可能影响我们对疾病发病机制的理解,并为 MM 预防信息提供依据。